这是一篇来自已证抗体库的有关
人类 S100A7的综述,是根据7篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合S100A7 抗体。
S100A7 同义词: PSOR1; S100A7c; protein S100-A7; psoriasin 1
圣克鲁斯生物技术
小鼠 单克隆(47C1068) | | 圣克鲁斯生物技术 S100A7抗体(SantaCruz, 47C1068)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 1). Proteomes (2017) ncbi |
小鼠 单克隆(H-8) | | 圣克鲁斯生物技术 S100A7抗体(Santa Cruz Biotechnology, sc-377084)被用于被用于免疫印迹在人类样品上浓度为1:100 (图 2d). Breast Cancer Res (2017) ncbi |
小鼠 单克隆(47C1068) | | 圣克鲁斯生物技术 S100A7抗体(Santa, sc52948)被用于被用于免疫印迹在人类样品上 (图 3g). Cancer Res (2016) ncbi |
小鼠 单克隆(47C1068) | - 免疫组化-石蜡切片; 人类; 1:500; 图 st1
| 圣克鲁斯生物技术 S100A7抗体(Santa Cruz, sc-52948)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:500 (图 st1). Oncogenesis (2015) ncbi |
小鼠 单克隆(47C1068) | | 圣克鲁斯生物技术 S100A7抗体(Santa Cruz Biotechnology, sc-52948)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:500. Int J Cancer (2014) ncbi |
LifeSpan Biosciences
小鼠 单克隆(47C1068) | | LifeSpan Biosciences S100A7抗体(LifeSpan BioSciences, 47C1068)被用于被用于免疫组化在人类样品上浓度为1:3000 (图 4e). Breast Cancer Res (2017) ncbi |
Novus Biologicals
小鼠 单克隆(47C1068) | - 免疫细胞化学; 人类; 图 1e
- 免疫印迹; 人类; 图 1f
| Novus Biologicals S100A7抗体(Imgenex, NBP2-24911)被用于被用于免疫细胞化学在人类样品上 (图 1e) 和 被用于免疫印迹在人类样品上 (图 1f). Cancer Gene Ther (2016) ncbi |
小鼠 单克隆(47C1068) | | Novus Biologicals S100A7抗体(Clinisciences, IMG-409A)被用于被用于免疫组化在人类样品上浓度为1:50 (图 4). PLoS ONE (2014) ncbi |
Pucci Minafra I, Di Cara G, Musso R, Cancemi P, Albanese N, Roz E,
et al. Retrospective Proteomic Screening of 100 Breast Cancer Tissues. Proteomes. 2017;5:
pubmed 出版商
Sakurai M, Miki Y, Takagi K, Suzuki T, Ishida T, Ohuchi N,
et al. Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment. Breast Cancer Res. 2017;19:70
pubmed 出版商
Dey K, Bharti R, Dey G, Pal I, Rajesh Y, Chavan S,
et al. S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway. Cancer Gene Ther. 2016;23:382-391
pubmed 出版商
Eichten A, Su J, Adler A, Zhang L, Ioffe E, Parveen A,
et al. Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade. Cancer Res. 2016;76:2327-39
pubmed 出版商
Chauhan S, Kaur J, Kumar M, Matta A, Srivastava G, Alyass A,
et al. Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer. Oncogenesis. 2015;4:e147
pubmed 出版商
Rabeony H, Petit Paris I, Garnier J, Barrault C, Pedretti N, Guilloteau K,
et al. Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1?, TNF? and oncostatin M. PLoS ONE. 2014;9:e101937
pubmed 出版商
Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I,
et al. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer. 2014;134:1379-88
pubmed 出版商